国家集采接续采购开标 美迪西股价近期波动显著

Group 1 - The core viewpoint of the news is that the national centralized procurement of medicines is expected to stabilize production and sales expectations in the pharmaceutical industry, with a high selection rate of 93% for the involved drugs [1] - The procurement involves 316 commonly used drugs across 26 treatment areas, including anti-infection and anti-tumor [1] - The procurement process is led by the National Healthcare Security Administration and will follow a unified national rule, with the procurement period extending until the end of 2028 [1] Group 2 - The stock price of Medisi has shown significant volatility in the recent trading days, with a peak increase of 7.20% on February 6, closing at 70.00 yuan [2] - On February 9, the stock price dropped by 4.29% to 67.00 yuan, influenced by market sentiment, followed by a slight increase of 0.28% on February 12, closing at 67.19 yuan [2] - The trading range for the stock during this period reached 21.97%, indicating active trading, with fluctuations in financing balance observed [2]